Metabolische Effekte und allgemeine Nebenwirkungen bei Endometriose-behandlung mit einem LHRH-Agonisten

Publisher Website
Google Scholar
Abstract
Between 1983 and 1986 40 patients were treated for external genital endometriosis with the LHRH agonist buserelin. Ovarian suppression was achieved for a period of six months with a dose of 900 to 1,800 mcg per day. In addition to gynecological findings, liver and kidney function and lipid metabolism were checked prior to treatment and at regular intervals during treatment. No deviations from normal ranges were found. The general side effects observed during treatment were as a rule attributable to the buserelin-induced relative estrogen deficiency. The efficacy of the medication in the treatment of endometriosis was demonstrtaed by control pelviscopy. Since no undesirable metbolic side effects have so far been observed with buserelin, it may be considered an effective new alternative treatment for endometriosis.